Video
Marika Falcone of San Raffaele Hospital in Milan discusses the growing evidence linking the gut microbiome to extra-intestinal autoimmune diseases.
Pierre Burguière, founder of Microbiome Futures, and Christian Roghi, founder of Bridgyz, reflect on a groundbreaking Pharmabiotics 2026 session dedicated to the intersection of microbiome science and space exploration.
Maurizio Vecchi, gastroenterologist at Policlinico of Milan (Italy), discussed the current and potential role of the microbiome in inflammatory bowel disease (IBD).
Gianfranco Grompone, Chief Scientific Officer at BioGaia GA, discusses the new evidences about oral microbiome.
Pregnancy: how dysbiosis may affect placentation, maternal immunity, and the risk of neonatal sepsis
Maria Rescigno (Humanitas University, Rozzano, Milan) discusses the role of dysbiosis during pregnancy and the perinatal period, outlining two potential clinical trajectories.
Industry, Gastroenterology
Sponsored by
How postbiotics are reshaping dietary supplements and pharma: key insights from Humiome® Post LB.
Francesco Franceschi from Policlinico Universitario A. Gemelli IRCCS (Roma) focuses on bacterial translocation across a compromised intestinal barrier as a plausible pathway contributing to sepsis.
William Fusco, gastroenterologist at Policlinico Universitario Agostino Gemelli, highlighted a recently published pilot study on post-infectious irritable bowel syndrome (IBS) framed within microbial precision medicine and biomarker-driven care.
Camille Bello, Communication and Membership Manager at Pharmabiotics Research Institute, underscores the conference’s regulatory focus and PRI’s role in guiding microbiome innovations through complex approval pathways.
Celine Druart, Executive Director at Pharmabiotic Research Institute, discusses the 10th Pharmabiotics Conference in Brussels, from microbiome biomarkers and One Health to key regulatory developments shaping live biotherapeutic products.
